Ritter Pharmaceuticals has partnered with the University of British Columbia (UBC)’s Michael Smith Laboratories in Canada to explore development of microbiome and RP-G28 in environmental enteropathy (EE).

As part of the collaboration, Ritter is providing its lead compound RP-G28 for use in the study and UBC microbiologist Dr B Brett Finlay will explore the microbiome’s role in EE. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest pre-clinical research has been designed to build upon Dr Finlay’s studies that were previously published, demonstrating the gut microbiome’s role in contributing to the causes of EE. 

Ritter Pharmaceuticals co-founder and president Andrew Ritter said: “We are pleased to be collaborating with Dr Finlay and his team to better understand therapeutic interventions that may reverse signs of environmental enteropathy, a significant worldwide health issue. 

"Testing RP-G28 in the relevant model will greatly facilitate preclinical testing of this compound for affecting the outcome of EE."

“We’re excited to apply our clinical knowledge of RP-G28 in a way that has significant possibilities to produce substantial social benefits in developing countries.”

At present, RP-G28 is in a Phase IIb/3 study in humans for the treatment of lactose intolerance and has demonstrated beneficial changes to the gut microbiome in earlier studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dr Finlay said: “We are pleased to be working with Ritter Pharmaceuticals to explore potential treatments and therapies to environmental enteropathy that affects so many of the world’s children. 

“Testing RP-G28 in the relevant model will greatly facilitate preclinical testing of this compound for affecting the outcome of EE.”

Ritter’s RP-G28 has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects people worldwide.